EMSAM
LOE Approachingselegiline
NDATRANSDERMALSYSTEM
Approved
Feb 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
EMSAM (selegiline) is (the drug substance of emsam) as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (cns) resulting from its irreversible inhibition of the enzyme monoamine oxidase (mao). Approved for major depressive disorder (mdd) (). First approved in 2006.
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMSAM is a transdermal selegiline patch approved in 2006 for major depressive disorder. It works as an irreversible monoamine oxidase (MAO) inhibitor, potentiating monoamine neurotransmitter activity in the central nervous system. The transdermal delivery system provides an alternative to oral antidepressants with a potentially differentiated side-effect profile.
LOE Approaching
With LOE approaching and modest competitive pressure (30), team focus is likely shifting toward transition planning and generic preparation rather than growth initiatives.
Mechanism of Action
(the drug substance of EMSAM) as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).
Indications (1)
Clinical Trials (2)
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Started Mar 2007
77 enrolled
Parkinson's Disease
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
127 enrolled
Cognition DisordersHIV Infections
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.